REM sleep changes in rats induced by siRNA-mediated orexin knockdown

Department of Psychiatry, Harvard Medical School, Boston VA Healthcare System, 940 Belmont Street, Brockton, MA 02301, USA, and Department of Neurology, Harry Truman Memorial VA Hospital, Columbia, MO 65203, USA.
European Journal of Neuroscience (Impact Factor: 3.18). 11/2006; 24(7):2039-48. DOI: 10.1111/j.1460-9568.2006.05058.x
Source: PubMed


Short interfering RNAs (siRNA) targeting prepro-orexin mRNA were microinjected into the rat perifornical hypothalamus. Prepro-orexin siRNA-treated rats had a significant (59%) reduction in prepro-orexin mRNA compared to scrambled siRNA-treated rats 2 days postinjection, whereas prodynorphin mRNA was unaffected. The number of orexin-A-positive neurons on the siRNA-treated side decreased significantly (23%) as compared to the contralateral control (scrambled siRNA-treated) side. Neither the colocalized dynorphin nor the neighbouring melanin-concentrating hormone neurons were affected. The number of orexin-A-positive neurons on the siRNA-treated side did not differ from the number on the control side 4 or 6 days postinjection. Behaviourally, there was a persistent (approximately 60%) increase in the amount of time spent in rapid eye movement (REM) sleep during the dark (active) period for 4 nights postinjection, in rats treated with prepro-orexin siRNA bilaterally. This increase occurred mainly because of an increased number of REM episodes and decrease in REM-to-REM interval. Cataplexy-like episodes were also observed in some of these animals. Wakefulness and NREM sleep were unaffected. The siRNA-induced increase in REM sleep during the dark cycle reverted to control values on the 5th day postinjection. In contrast, the scrambled siRNA-treated animals only had a transient increase in REM sleep for the first postinjection night. Our results indicate that siRNA can be usefully employed in behavioural studies to complement other loss-of-function approaches. Moreover, these data suggest that the orexin system plays a role in the diurnal gating of REM sleep.

Download full-text


Available from: Mahesh M Thakkar, Jan 10, 2014
    • "It has been shown that in vivo siRNA injection results in specific knockdown of mammalian genes (Chen et al. 2006). We evaluated the level of Nrf1 by Western blotting, 4 and 8 h after Nrf1-siRNA injection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anxiety-related disorders are complex illnesses that underlying molecular mechanisms need to be understood. Mitochondria stand as an important link between energy metabolism, oxidative stress, and anxiety. The nuclear factor, erythroid-derived 2,-like 1(Nrf1) is a member of the cap "n" collar subfamily of basic region leucine zipper transcription factors and plays the major role in regulating the adaptive response to oxidants and electrophiles within the cell. Here, we injected small interfering RNA (siRNA) targeting Nrf1 in dorsal third ventricle of adult male albino Wistar rats and subsequently examined the effect of this silencing on anxiety-related behavior. We also evaluated apoptotic markers and mitochondrial biogenesis factors, along with electron transport chain activity in three brain regions: hippocampus, amygdala, and prefrontal cortex. Our data revealed that in the group that received Nrf1-siRNA, anxiety-related behavior did not show any significant changes compared to the control group. Caspase-3 did not increase in Nrf1-siRNA-injected rats even though Bax/Bcl2 ratio markedly elevated in Nrf1-knockdown rats in all three mentioned regions compared to control rats. Also, Nrf1 silencing of complex I and II-III did not alter, generally. In addition, Nrf1-knockdown affected mitochondrial biogenesis markers. The level of peroxisome proliferator-activated receptor gamma coactivator-1α and cytochrome-c increased, which indicates a possible role for mitochondrial biogenesis in anxiety.
    Cellular and Molecular Neurobiology 07/2015; DOI:10.1007/s10571-015-0236-0 · 2.51 Impact Factor
  • Source
    • "Hypocretin cell loss in PD correlates with disease severity (Thannickal et al., 2007) and is present, even if less pronounced, at earlier disease stages. Moreover, rodent studies showed that a partial hypocretin loss is sufficient for the presence of REM sleep disturbances (Chen et al., 2006; Gerashchenko et al., 2003). As a neurodegenerative disease, PD affects mainly older adults, whereas narcolepsy, as a presumed autoimmune disorder, begins in most cases in the second or third decade. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The striatum and the prefrontal cortex play an important role in cognitive time processing, and time perception depends on sustained attention. Narcolepsy patients are unable to maintain sustained attention, due probably to deficient hypocretin signalling. Impaired time perception has been found in Parkinson's disease (PD) and attributed to a dysfunctional dopaminergic striatal pacemaker. We aimed to assess time perception in patients with narcolepsy and PD and to compare the outcome to healthy control participants. Seventeen narcolepsy patients, 12 PD patients and 15 healthy controls performed a short time production task, where they had to produce an interval of 1, 2 or 5 s. The accuracy of time production differed significantly according to task target duration, and there was a trend towards a group difference with narcolepsy patients tending to overproduce all target durations. Absolute variability was significantly different between groups, with narcolepsy patients showing higher absolute variability in comparison to controls and PD patients. The analysis of the temporal course of time estimation showed more pronounced overproduction of each target duration at the end of each trial in narcolepsy patients, whereas performance was more or less stable in controls and PD patients. Overproduction and higher variability of all time durations in narcolepsy indicate impaired short interval timing in the seconds range, while the scalar property of timing was preserved. The time-course of accuracy and variability of time production within sessions indicate an attention-related mechanism of impaired interval timing.
    Journal of Sleep Research 07/2013; 22(6). DOI:10.1111/jsr.12069 · 3.35 Impact Factor
  • Source
    • "In this case, knockdown of orexin was determined by immunohistochemical staining for orexin as well as melaninconcentrating hormone (MCH). MCH is expressed in interdigitated non-orexin neurons in the orexin cell field of the LH, and thus provides a good measure of the specificity of knockdown (Chen et al., 2006). One microinjection of morpholinos (0.3 ␮l, 150 nmol) was sufficient to suppress orexin protein expression, but had no effect on MCH expression (Figs. 4 and 5). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.
    Journal of Neuroscience Methods 01/2012; 203(2):354-60. DOI:10.1016/j.jneumeth.2011.10.009 · 2.05 Impact Factor
Show more